semaglutide heart health and Cardiovascular The weight-loss drug Wegovy lowered

Keeping a journal can be helpful

A study from the Employee Benefit Research Institute estimates that expanding GLP-1 coverage would drive health plan premiums up between 5% and 14%, depending on adherence and eligibility

[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Haider S., Lipska K.J

GLP-1 Medications Linked to Serious Health Complications While GLP-1 receptor agonist drugs such as Ozempic, Wegovy, Rybelsus, and Mounjaro have been widely promoted for their weight loss benefits and ability to treat type 2 diabetes, many patients have reported severe health issues after taking these medications

can be serious if not treated promptly